An experimental approach to study the function of mitochondria in cardiomyopathy

키워드

참고문헌 (97)

1. Walters AM, "Mitochondria as a drug target in ischemic heart disease and cardiomyopathy", Circ Res, 111, pp.1222~1236 (2012)
2. Roger VL, "Heart disease and stroke statistics--2012 update: a report from the American Heart Association", Circulation, 125, pp.2~220 (2012)
3. Ambrosio G, "Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow", J Biol Chem, 268, pp.18532~18541 (1993)
4. Lucas DT, "Cardiac reperfusion injury:aging, lipid peroxidation, and mitochondrial dysfunction", Proc Natl Acad Sci U S A, 95, pp.510~514 (1998)
5. Murphy E, "Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury", Physiol Rev 88, 88, pp.581~609 (2008)
6. Brenner C, "Physiological roles of the permeability transition pore", Circ Res, 111, pp.1237~1247 (2012)
7. Kwong JQ, "Physiological and pathological roles of the mitochondrial permeability transition pore in the heart", Cell Metab, 21, pp.206~214 (2015)
8. Huss JM, "Mitochondrial energy metabolism in heart failure: a question of balance", J Clin Invest, 115, pp.547~555 (2005)
9. Towbin JA, "The failing heart", Nature, 415, pp.227~233 (2002)
10. Cecchi F, "Clinical and molecular classification of cardiomyopathies", Glob Cardiol Sci Pract, 2012, pp.4~ (2012)
11. Ozawa T, "Mitochondrial cardiomyopathy", Herz, 19, pp.105~118 (1994)
12. Stanley WC, "Mitochondrial dysfunction in heart failure: potential for therapeutic interventions?", Cardiovasc Res, 45, pp.805~806 (2000)
13. Lesnefsky EJ, "Mitochondrial dysfunction in cardiac disease: ischemia--reperfusion, aging, and heart failure", J Mol Cell Cardiol, 33, pp.1065~1089 (2001)
14. Ikeda Y, "Models of dilated cardiomyopathy in the mouse and the hamster", Curr Opin Cardiol, 15, pp.197~201 (2000)
15. Benjamin IJ, "Learning from failure:congestive heart failure in the postgenomic age", J Clin Invest, 115, pp.495~499 (2005)
16. Recchia FA, "Animal models of dilated cardiomyopathy for translational research", Vet Res Commun, 31(1), pp.35~41 (2007)
17. Wallace DC, "Energetics, epigenetics, mitochondrial genetics", Mitochondrion, 10, pp.12~31 (2010)
18. Winnik S, "Protective effects of sirtuins in cardiovascular diseases:from bench to bedside", Eur Heart J (2015)
19. Ryu D, "A SIRT7-dependent acetylation switch of GABPbeta1 controls mitochondrial function", Cell Metab, 20, pp.856~869 (2014)
20. Roh JI, "Perturbation of NCOA6 leads to dilated cardiomyopathy", Cell Rep, 8, pp.991~998 (2014)
21. Lauritzen KH, "Impaired dynamics and function of mitochondria caused by mtDNA toxicity leads to heart failure", Am J Physiol Heart Circ Physiol, 309, pp.434~449 (2015)
22. Sligh JE, "Maternal germ-line transmission of mutant mtDNAs from embryonic stem cell-derived chimeric mice", Proc Natl Acad Sci U S A, 97, pp.14461~14466 (2000)
23. Baba A, "Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy", Eur Heart J, 25, pp.1108~1115 (2004)
24. Fu LX, "Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy", J Clin Invest, 91, pp.1964~1968 (1993)
25. Fu ML, "Functional epitope analysis of the second extracellular loop of the human heart muscarinic acetylcholine receptor", J Mol Cell Cardiol, 27, pp.427~436 (1995)
26. Zhang S, "Mitochondrial Ultrastructural Alterations and Declined M2 Receptor Density Were Involved in Cardiac Dysfunction in Rats after Long Term Treatment with Autoantibodies against M2Muscarinic Receptor", PLoS One, 10, pp.e0129563~ (2015)
27. Yoshizawa A, "Autoimmunity against M(2)muscarinic acetylcholine receptor induces myocarditis and leads to a dilated cardiomyopathy-like phenotype", Eur J Immunol, 42, pp.1152~1163 (2012)
28. Palmer JW, "Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle", J Biol Chem, 252, pp.8731~8739 (1977)
29. Shin G, "Detection of mitochondrial membrane damages in myocardial ischemia with ESR spin labeling technique", J Mol Cell Cardiol, 21, pp.1029~1036 (1989)
30. Palmer JW, "Biochemical differences between subsarcolemmal and interfibrillar mitochondria from rat cardiac muscle: effects of procedural manipulations", Arch Biochem Biophys, 236, pp.691~702 (1985)
31. Hoppel CL, "Hamster cardiomyopathy. A defect in oxidative phosphorylation in the cardiac interfibrillar mitochondria", J Biol Chem, 257, pp.1540~1548 (1982)
32. D'Angelo DD, "Transgenic Galphaq overexpression induces cardiac contractile failure in mice", Proc Natl Acad Sci U S A, 94, pp.8121~8126 (1997)
33. Sakata Y, "Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice", Circulation, 97, pp.1488~1495 (1998)
34. Yussman MG, "Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy", Nat Med, 8, pp.725~730 (2002)
35. Syed F, "Physiological growth synergizes with pathological genes in experimental cardiomyopathy", Circ Res, 95, pp.1200~1206 (2004)
36. Diwan A, "Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation", Circulation, 117, pp.396~404 (2008)
37. Dorn GW 2nd, "Mitochondrial pruning by Nix and BNip3: an essential function for cardiac-expressed death factors", J Cardiovasc Transl Res, 3, pp.374~383 (2010)
38. Archer SL, "Mitochondrial dynamics--mitochondrial fission and fusion in human diseases", N Engl J Med, 369, pp.2236~2251 (2013)
39. Song M, "Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts", Cell Metab, 21, pp.273~285 (2015)
40. Chen Y, "PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria", Science, 340, pp.471~475 (2013)
41. Song M, "Super-suppression of mitochondrial reactive oxygen species signaling impairs compensatory autophagy in primary mitophagic cardiomyopathy", Circ Res, 115, pp.348~353 (2014)
42. Chen Y, "Mitochondrial fusion is essential for organelle function and cardiac homeostasis", Circ Res, 109, pp.1327~1331 (2011)
43. Papanicolaou KN, "Mitofusins 1 and 2 are essential for postnatal metabolic remodeling in heart", Circ Res, 111, pp.1012~1026 (2012)
44. Chen L, "OPA1 mutation and late-onset cardiomyopathy: mitochondrial dysfunction and mtDNA instability", J Am Heart Assoc, 1, pp.e003012~ (2012)
45. Song M, "Mitoconfusion : noncanonical functioning of dynamism factors in static mitochondria of the heart", Cell Metab, 21, pp.195~205 (2015)
46. Kubli DA, "Mitochondria and mitophagy:the yin and yang of cell death control", Circ Res, 111, pp.1208~1221 (2012)
47. Delbridge LM, "Myocardial autophagic energy stress responses--macroautophagy, mitophagy, and glycophagy", Am J Physiol Heart Circ Physiol, 308, pp.1194~1204 (2015)
48. Shirihai OS, "How Mitochondrial Dynamism Orchestrates Mitophagy", Circ Res, 116, pp.1835~1849 (2015)
49. Ashrafian H, "A mutation in the mitochondrial fission gene Dnm1l leads to cardiomyopathy", PLoS Genet, 6, pp.e1001000~ (2010)
50. Gray MW, "Mitochondrial evolution", Science, 283, pp.1476~1481 (1999)
51. Fosslien E, "Review : Mitochondrial medicine--cardiomyopathy caused by defective oxidative phosphorylation", Ann Clin Lab Sci, 33, pp.371~395 (2003)
52. Wang J, "Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression", Nat Genet, 21, pp.133~137 (1999)
53. Li H, "Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy", Proc Natl Acad Sci U S A, 97, pp.3467~3472 (2000)
54. Wisneski JA, "Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans", J Clin Invest, 79, pp.359~366 (1987)
55. Stanley WC, "Energy metabolism in the normal and failing heart: potential for therapeutic interventions", Heart Fail Rev, 7, pp.115~130 (2002)
56. Stanley WC, "Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions", Cardiovasc Res, 33, pp.243~257 (1997)
57. Graham BH, "A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart", muscle isoform of the adenine nucleotide translocator, 1997, pp.16, 226~234
58. Engel AG, "Myofibrillar myopathy", Ann Neurol, 46, pp.681~683 (1999)
59. Paulin D, "Desminopathies in muscle disease", J Pathol, 204, pp.418~427 (2004)
60. Vicart P, "A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy", Nat Genet, 20, pp.92~95 (1998)
61. Wang X, "Mouse model of desmin-related cardiomyopathy", Circulation, 103, pp.2402~2407 (2001)
62. Maloyan A, "Mitochondrial dysfunction and apoptosis underlie the pathogenic process in alpha-B-crystallin desmin-related cardiomyopathy", Circulation, 112, pp.3451~3461 (2005)
63. Badorff C, "Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy", Nat Med, 5, pp.320~326 (1999)
64. Feng J, "Mutations in the dystrophin gene are associated with sporadic dilated cardiomyopathy", Mol Genet Metab, 77, pp.119~126 (2002)
65. Vatta M, "Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy", Lancet, 359, pp.936~941 (2002)
66. Khairallah M, "Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy", J Mol Cell Cardiol, 43, pp.119~129 (2007)
67. Nakayama H, "Ca2+-and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure", J Clin Invest, 117, pp.2431~2444 (2007)
68. Hajjar RJ, "Pathophysiological and biochemical characterisation of an avian model of dilated cardiomyopathy:comparison to findings in human dilated cardiomyopathy", Cardiovasc Res, 27, pp.2212~2221 (1993)
69. Zhang M, "Calreticulin-STAT3signaling pathway modulates mitochondrial function in a rat model of furazolidone-induced dilated cardiomyopathy", PLoS One, 8, pp.e66779~ (2013)
70. Armstrong PW, "Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure", Circulation, 74, pp.1075~1084 (1986)
71. Spinale FG, "Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine", Am J Physiol, 259, pp.218~229 (1990)
72. Ide T, "Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium", Circ Res, 85, pp.357~363 (1999)
73. Melov S, "Mitochondrial disease in superoxide dismutase 2 mutant mice", Proc Natl Acad Sci U S A, 96, pp.846~851 (1999)
74. Lefrak EA, "A clinicopathologic analysis of adriamycin cardiotoxicity", Cancer, 32, pp.302~314 (1973)
75. Gilladoga AC, "The cardiotoxicity of adriamycin and daunomycin in children", Cancer, 37, pp.1070~1078 (1976)
76. Takemura G, "Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management", Prog Cardiovasc Dis, 49, pp.330~352 (2007)
77. Sawyer DB, "Anthracyclines and heart failure", N Engl J Med, 368, pp.1154~1156 (2013)
78. van der Vijgh WJ, "Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice", Eur J Cancer Clin Oncol, 24, pp.1603~1608 (1988)
79. Shenasa H, "Chronic doxorubicin induced cardiomyopathy in rabbits:mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium", Cardiovasc Res, 24, pp.591~604 (1990)
80. Lebrecht D, "Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy", Circulation, 108, pp.2423~2429 (2003)
81. Kerr DS, "Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade", Mol Genet Metab, 99, pp.246~255 (2010)
82. Gurlek A, "The effects of L-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy", Eur J Heart Fail, 2, pp.189~193 (2000)
83. Singh RB, "Coenzyme Q in cardiovascular disease", J Assoc Physicians India, 46, pp.299~306 (1998)
84. Buyse GM, "Longterm blinded placebo-controlled study of SNT-MC17", idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance, 2009, pp.30, 116~124
85. Lagedrost SJ, "Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study(IONIA)", Am Heart J, 161, pp.639~645 (2011)
86. Rizos I, "Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration", Am Heart J, 139, pp.120~123 (2000)
87. Abozguia K, "Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy", Circulation, 122, pp.1562~1569 (2010)
88. Lionetti V, "Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure", Cardiovasc Res, 66, pp.454~461 (2005)
89. Bersin RM, "Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate", J Am Coll Cardiol, 23, pp.1617~1624 (1994)
90. Lewis JF, "Effects of dichloroacetate in patients with congestive heart failure", Clin Cardiol, 21, pp.888~892 (1998)
91. Arakawa K, "Abnormal myocardial energy-production state in mitochondrial cardiomyopathy and acute response to L-arginine infusion. C-11 acetate kinetics revealed by positron emission tomography", Circ J, 74, pp.2702~2711 (2010)
92. Lebrecht D, "Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats", Br J Pharmacol, 151, pp.771~778 (2007)
93. Konorev EA, "Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates", Arch Biochem Biophys, 368, pp.421~428 (1999)
94. Fisher PW, "Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity", Circulation, 111, pp.1601~1610 (2005)
95. Wagner JA, "Alterations in calcium antagonist receptors and sodium-calcium exchange in cardiomyopathic hamster tissues", Circ Res, 65, pp.205~214 (1989)
96. Li Y, "Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase", Nat Genet, 11, pp.376~381 (1995)
97. Shipp JC, "Fatty acid and glucose metabolism in the perfused heart", Nature, 189, pp.1018~1019 (1961)

관련 논문AI추천